Longliv Ventures

Operator of a digital online platform intended to assist patients in treating themselves with OTC medications. The company's platform allows users quickly and discreetly, to learn more about their condition, identify issues that should be escalated to a healthcare provider, check for allergies and potential sensitivities to ingredients of OTC medications, and purchase an appropriate product, enabling customers to choose a suitable drug out of a large offering, while helping them to take into consideration any related medical condition.

AceAge is a healthcare technology company focused on enhancing health outcomes for aging individuals through innovative products. The company's flagship product, Karie, is a home health appliance designed to help users manage their medication routines effectively. Karie organizes, schedules, and dispenses pills with one-button control, addressing the critical issue of medication nonadherence, which costs the U.S. healthcare system approximately $290 billion annually. By automating daily medication routines, Karie minimizes human error and supports greater patient autonomy, ultimately improving compliance with prescribed medical directions. The device utilizes common multi-dose pouch packaging that can be pre-set by pharmacists, ensuring that doses are delivered and monitored accurately. Through its user-friendly design, AceAge aims to enhance patient health while reducing the necessity for emergency care visits and assisted living admissions.

Sight Diagnostics Ltd. is a medical device company based in Tel Aviv, Israel, that focuses on developing advanced diagnostic solutions for blood diseases. Utilizing proprietary machine-vision technology, the company has created a platform that leverages artificial intelligence for blood analysis and infectious disease detection. Its flagship product, Parasight, is a malaria detection device that accurately identifies and enumerates malaria through a digital fluorescent microscopy process. Since its launch in 2014, Sight Diagnostics has sold over 600,000 tests across 25 countries. Additionally, the company has introduced OLO, a device that facilitates complete blood count testing at the point-of-care, which is currently available in the European Union and other non-US markets. By providing scalable and precise blood diagnostics, Sight Diagnostics aims to enhance patient outcomes and improve overall healthcare accessibility.

DayTwo Ltd. is a precision medicine company based in Tel Aviv-Yafo, Israel, that focuses on using gut microbiome analysis to provide personalized health solutions for metabolic diseases such as diabetes, prediabetes, and obesity. Founded in 2015, the company utilizes gut microbiome sequencing to create tailored Food Prescriptions™ that help individuals manage their blood sugar levels, improve energy, and achieve weight loss. Their digital platform offers actionable dietary recommendations based on individual biometrics and lifestyle factors, ensuring that patients receive insights that are practical and easy to follow. DayTwo also employs a telehealth service, where Certified Diabetes Care and Education Specialists and Registered Dietitians support patients through a smartphone application, allowing for progress tracking and communication. The effectiveness of DayTwo's approach is measured using clinical outcomes such as A1C levels and Time In Range, with the potential for full fee reimbursement for those who adhere to the protocol.

DayTwo Ltd. is a precision medicine company based in Tel Aviv-Yafo, Israel, that focuses on using gut microbiome analysis to provide personalized health solutions for metabolic diseases such as diabetes, prediabetes, and obesity. Founded in 2015, the company utilizes gut microbiome sequencing to create tailored Food Prescriptions™ that help individuals manage their blood sugar levels, improve energy, and achieve weight loss. Their digital platform offers actionable dietary recommendations based on individual biometrics and lifestyle factors, ensuring that patients receive insights that are practical and easy to follow. DayTwo also employs a telehealth service, where Certified Diabetes Care and Education Specialists and Registered Dietitians support patients through a smartphone application, allowing for progress tracking and communication. The effectiveness of DayTwo's approach is measured using clinical outcomes such as A1C levels and Time In Range, with the potential for full fee reimbursement for those who adhere to the protocol.

Sight Diagnostics Ltd. is a medical device company based in Tel Aviv, Israel, that focuses on developing advanced diagnostic solutions for blood diseases. Utilizing proprietary machine-vision technology, the company has created a platform that leverages artificial intelligence for blood analysis and infectious disease detection. Its flagship product, Parasight, is a malaria detection device that accurately identifies and enumerates malaria through a digital fluorescent microscopy process. Since its launch in 2014, Sight Diagnostics has sold over 600,000 tests across 25 countries. Additionally, the company has introduced OLO, a device that facilitates complete blood count testing at the point-of-care, which is currently available in the European Union and other non-US markets. By providing scalable and precise blood diagnostics, Sight Diagnostics aims to enhance patient outcomes and improve overall healthcare accessibility.